Adicet Bio Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Adicet Bio Inc 's ROA in the third quarter of 2026?
Adicet Bio Inc recorded a cumulative net loss of $-96 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -53.47%.

However, within the Healthcare sector 646 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4112, from total ROA ranking in the first quarter of 2026 at 4814.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	34.77 %	-11.44 %	-6.92 %	-42.89 %	-35.68 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-96	-109	-117	-115	-119
Return On Assets (TTM)	-53.47 %	-65.44 %	-68 %	-65.59 %	-58.81 %
ACET's Total Ranking	# 4112	# 4814	# 4197	# 4187	# 4189
Total Assets (TTM) in million	220	169	192	140	163
Seq. Total Assets Change	29.67 %	-11.94 %	36.93 %	-13.8 %	-14.8 %
Seq. Net Income Change	-	-	-	-	-

ACET's 5 Years Annual ROA >> Back to ACET Management Effectiveness >> Compare ACET ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 294
Sector	# 647
Overall	# 4072

Return On Assets Statistics
High	Average	Low
65.38 %	-13.78 %	-68 %
(Sep 30 2021)		(Dec 31 2025)

Financial Statements
Adicet Bio Inc 's Assets	$ 220 million	ACET's Balance sheet
Adicet Bio Inc 's Income	$ -19 million	Quarterly ACET's Income Statement
ACET's Income by Division		See ACET's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-6.92 %	8.17 %	-38.61 %	-2.61 %	143.17 %
Total Assets in million	192	207	191	311	320
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-117	-117	-143	-70	-62
Annual Return On Assets	-60.72 %	-56.67 %	-74.67 %	-22.43 %	-19.4 %

ACET's 5 Years Annual ROA >> Back to ACET Management Effectiveness >> Compare ACET ROA to its Competitors

More Return On Assets Ratios
ACET's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACET's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACET's Competitors
Subscribers only: Roa for Adicet Bio Inc 's Suppliers
Subscribers only: Return On Assets for ACET's Customers

You may also want to know
ACET's Roi	ACET's Inventory Turnover Ratio	ACET's Growth Rates	ACET's Dividend Comparisons
	ACET's Profitability Ratios	ACET's Asset Turnover Ratio	ACET's Dividend Growth
ACET's Roe	ACET's Valuation Ratios	ACET's Financial Strength Ratios	ACET's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-06T05:53:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.